Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article, J Pharm Drug Deliv Res Vol: 1 Issue: 1
Development of a Nanoporous Elastomere Intra-Vaginal Ring (IVR) for the Sustained Release of Non-Hormonal Contraceptives
| Saxena Brij B1*, Koldras Kristen E1, Singh Mukul1, Nguyen Nancy1, Rathnam Premila1, Ledger William J1 and Lerner Sidney2 |
| 1Weill Cornell Medical College, Department of Obstetrics and Gynecology, 515 East 71st Street, S-412, NY 10021, USA |
| 2BioRings, LLC, 215 Lexington Avenue Room 1001, NY 10016, USA |
| Corresponding author : Saxena Brij B Weill Cornell Medical College, Department of Obstetrics and Gynecology, 515 East 71st Street, S-412, NY 10021, USA Tel: (212) 746-3067; Fax: (212) 746-4964 E-mail: brs2003@med.cornell.edu |
| Received: March 26, 2012 Accepted: September 07, 2012 Published: September 10, 2012 |
| Citation: Saxena Brij B, Koldras Kristen E, Mukul S, Nancy N, Premila R, et al. (2012) Development of a Nanoporous Elastomere Intra-Vaginal Ring (IVR) for the Sustained Release of Non-Hormonal Contraceptives. J Pharm Drug Deliv Res 1:1. doi:10.4172/2325-9604.1000104 |
Abstract
Development of a Nanoporous Elastomere Intra-Vaginal Ring (IVR) for the Sustained Release of Non-Hormonal Contraceptives
The goal of this investigation is the development a new biocompatible intra-vaginal ring (IVR) composed of nanoporous poly (diol citrate)elastomeres for a sustained release of nonhormonal contraceptives, namely ferrous gluconate to cause spermiostasis, ascorbic acid to increase cervical mucus viscosity, and a mixture of ampholines and/or poly L-glutamic acid (PGLA) buffer to sustain the pH at 4 to cause spermiostasis within 30 seconds, for the prevention of undesired pregnancy. The IVR of 5.5 cm in diameter and a rim of 0.5 cm is cast in a mold. The daily eluates of the IVR are tested for pH, spermiostatic and/or spermicidal activity and effect on the viscosity of cervical mucus. Results of this study are efficacious in vitro; the IVR has a shelf life of one year and provides the basis for the newly developed IVR containing non-hormonal contraceptives for in vivo use in women to prevent undesired pregnancy as well as pelvic and HIV infection simultaneously or HIV infection alone.
